A Phase II Study of Afatinib (BIBW 2992) in Patients with Adenocarcinoma of the Lung and Activating EGFR/HER1 Mutations (LUX-Lung 2)

被引：0
|
作者：
Yang, Chih-Hsin [1 ]
Shih, Jin Yuan [1 ]
Su, Wu-Chou [2 ]
Hsia, Te-Chun [3 ]
Sequist, Lecia V. [4 ]
Chang, Gee-Chen [5 ]
Calvo, Roser
Cong, Xiuyu Julie
Shahidi, Mehdi
Miller, Vincent A. [6 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[3] China Med Univ Hosp, Dept Internal Med, Taichung, Taiwan
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Taichung Vet Gen Hosp, Dept Internal Med, Taichung, Taiwan
[6] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S376 / S377
页数：2
相关论文
共 50 条
  • [31] A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer
    Janjigian, Yelena Yuriy
    Ilson, David
    Kelsen, David Paul
    Schattner, Mark
    Heguy, Adriana
    Vakiani, Efsevia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3
    Kato, Terufumi
    Yoshioka, Hiroshige
    Okamoto, Isamu
    Yokoyama, Akira
    Hida, Toyoaki
    Seto, Takashi
    Kiura, Katsuyuki
    Massey, Dan
    Seki, Yoko
    Yamamoto, Nobuyuki
    CANCER SCIENCE, 2015, 106 (09) : 1202 - 1211
  • [33] Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
    Yang, James Chih-Hsin
    Wu, Yi-Long
    Schuler, Martin
    Sebastian, Martin
    Popat, Sanjay
    Yamamoto, Nobuyuki
    Zhou, Caicun
    Hu, Cheng-Ping
    O'Byrne, Kenneth
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Geater, Sarayut L.
    Lee, Kye Young
    Tsai, Chun-Ming
    Gorbunova, Vera
    Hirsh, Vera
    Bennouna, Jaafar
    Orlov, Sergey
    Mok, Tony
    Boyer, Michael
    Su, Wu-Chou
    Lee, Ki Hyeong
    Kato, Terufumi
    Massey, Dan
    Shahidi, Mehdi
    Zazulina, Victoria
    Sequist, Lecia V.
    LANCET ONCOLOGY, 2015, 16 (02): : 141 - 151
  • [34] Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
    Sequist, Lecia V.
    Yang, James Chih-Hsin
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Hirsh, Vera
    Mok, Tony
    Geater, Sarayut Lucien
    Orlov, Sergey
    Tsai, Chun-Ming
    Boyer, Michael
    Su, Wu-Chou
    Bennouna, Jaafar
    Kato, Terufumi
    Gorbunova, Vera
    Lee, Ki Hyeong
    Shah, Riyaz
    Massey, Dan
    Zazulina, Victoria
    Shahidi, Mehdi
    Schuler, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3327 - +
  • [35] Subgroup Analysis of LUX-Lung 1: A Randomized Phase III Trial of Afatinib (BIBW 2992) + Best Supportive Care (BSC) versus Placebo plus BSC in Patients with NSCLC Failing 1-2 Lines of Chemotherapy and Erlotinib or Gefitinib
    Miller, V. A.
    Hirsch, V.
    Cadranel, J.
    Chen, Y.
    Park, K.
    Kim, S.
    Lorence, R.
    Shaidi, M.
    Cong, J.
    Yang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S557 - S558
  • [36] Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC
    Finocchiaro, G.
    Santoro, A.
    Grossi, F.
    Bidoli, P.
    Favaretto, A.
    Clementi, L.
    Massey, D.
    Lorence, R.
    Cappuzzo, F.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S593 - S594
  • [37] Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes
    Goss, G. D.
    Felip, E.
    Cobo, M.
    Lu, S.
    Syrigos, K.
    Li, K. W.
    Zhou, C.
    Park, K.
    Solca, F.
    Kraemer, N.
    Chand, V. K.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S626 - S626
  • [38] HER-2 Mutations in Chinese Lung Adenocarcinoma Patients with Negative EGFR Mutations
    Zhou, Caicun
    Li, Xuefei
    Zhao, Chao
    Ren, Shengxiang
    Su, Chunxia
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S705 - S705
  • [39] LUX-LUNG 3: AFATINIB VERSUS CISPLATIN AND PEMETREXED IN ASIAN PATIENTS WITH ADENOCARCINOMA OF THE LUNG HARBOURING AN EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION
    Mok, Tony
    Schuler, M.
    Yamamoto, Nobuyuki
    O'Byrne, K.
    Lirsh, Vera I.
    Grater, S. L.
    Tsai, C-m
    Kato, T.
    Su, W-c
    Lee, K. H.
    Lin, M-c
    Sirisinha, T.
    Parra, J.
    Yoshioka, H.
    Massey, D.
    Shahidi, M.
    Zazulina, V.
    Sequist, L. V.
    Yang, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S445 - S445
  • [40] Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut): Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    Wu, Y. -L.
    Sequist, L. V.
    Schuler, M.
    Yamamoto, N.
    Zhou, C.
    Hu, C. -P.
    O'Byrne, K.
    Hirsh, V.
    Mok, T.
    Zazulina, V.
    Yang, J. C. -H.
    ANNALS OF ONCOLOGY, 2015, 26 : 136 - 136
12345